SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical ...
In addition to orelabrutinib, we have fortified our powerful discovery engine to focus on cutting-edge targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with ...
Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results